Summary
Vertex Pharmaceuticals Inc. reported its financial results for the quarter ended March 31, 2010, showing a net loss of $165.3 million, or $0.83 per share, compared to a net loss of $162.7 million, or $1.04 per share, in the same period of the prior year. The widened net loss was primarily driven by a decrease in total revenues, down 6% to $22.4 million, largely due to a significant drop in collaborative revenues from Janssen, partially offset by increased royalty revenues and a substantial boost in collaborative revenues from Mitsubishi Tanabe. Significant ongoing investments in research and development, totaling $143.0 million for the quarter, continue to be a major expenditure. The company is advancing its lead drug candidate, telaprevir, with expected NDA submission in the second half of 2010. Other key pipeline programs include VX-770 for cystic fibrosis. While cash reserves remain substantial at $1.1 billion, the company anticipates continued losses and the potential need for future capital raises, dependent on the success and timelines of its drug development programs, particularly telaprevir.
Financial Highlights
41 data points| Revenue | $22.43M |
| R&D Expenses | $143.01M |
| SG&A Expenses | $35.55M |
| Operating Expenses | $182.71M |
| Operating Income | -$160.28M |
| Interest Expense | $3.96M |
| Net Income | -$165.27M |
| EPS (Basic) | $-0.83 |
| EPS (Diluted) | $-0.83 |
| Shares Outstanding (Basic) | 198.94M |
| Shares Outstanding (Diluted) | 198.94M |
Key Highlights
- 1Reported a net loss of $165.3 million ($0.83/share) for Q1 2010, a slight increase from $162.7 million ($1.04/share) in Q1 2009.
- 2Total revenues decreased by 6% to $22.4 million, primarily due to a 62% decline in collaborative revenues from Janssen, partially offset by higher royalty revenues and increased Mitsubishi Tanabe collaboration revenue.
- 3Research and development expenses remained high at $143.0 million, consistent with the prior year's quarter, reflecting continued investment in pipeline development.
- 4The company expects to submit its New Drug Application (NDA) for telaprevir in the second half of 2010, with potential product sales commencing in 2011 if approved.
- 5Cash, cash equivalents, and marketable securities stood at $1.1 billion as of March 31, 2010, providing a runway for at least the next twelve months.
- 6Sales, General, and Administrative (SG&A) expenses increased by 25% to $35.6 million, indicating preparations for potential commercialization activities.